Open Actively Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

About

Brief Summary
Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
21-000499
Category
Other Cancer
Contact
Tina Tieu
Location
  • UCLA Santa Monica
For Providers
NCT No.
NCT04762641
For detailed technical eligibility, visit ClinicalTrials.gov.